

CITATION REPORT

List of articles citing

Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes

DOI: 10.1111/liv.13872

Liver International, 2018, 38, 2018-2027.

Source: <https://exaly.com/paper-pdf/71232535/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
75	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 849-866	4.2	24
74	Metformin and Aging: A Review. <i>Gerontology</i> , 2019 , 65, 581-590	5.5	57
73	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019 , 39, 714-726	7.9	28
72	Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919848184	5.4	24
71	Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 317-328	6.1	29
70	Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	72
69	Hepatoprotective activity of metformin: A new mission for an old drug?. <i>European Journal of Pharmacology</i> , 2019 , 850, 1-7	5.3	26
68	Signaling through non-membrane nuclear phosphoinositide binding proteins in human health and disease. <i>Journal of Lipid Research</i> , 2019 , 60, 299-311	6.3	9
67	Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes. <i>Annals of Hepatology</i> , 2020 , 19, 320-328	3.1	13
66	Letter to the Editor: Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Steatohepatitis Cirrhosis and Diabetes: Insufficient for Individual Management. <i>Hepatology</i> , 2020 , 72, 361-362	11.2	1
65	Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020 , 24, 549-576	4.6	4
64	Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00236	4.2	9
63	Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2020 , 11, 6437-6444	4.5	4
62	Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes. <i>Frontiers in Oncology</i> , 2020 , 10, 587666	5.3	3
61	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
60	Matrix Stiffness-Upregulated MicroRNA-17-5p Attenuates the Intervention Effects of Metformin on HCC Invasion and Metastasis by Targeting the PTEN/PI3K/Akt Pathway. <i>Frontiers in Oncology</i> , 2020 , 10, 1563	5.3	9
59	The genetic association between type 2 diabetic and hepatocellular carcinomas. <i>Annals of Translational Medicine</i> , 2020 , 8, 380	3.2	6

58	Association between Aspirin and Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 382, 2480-2481	59.2	1
57	The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
56	Epidemiology and surveillance for hepatocellular carcinoma: New trends. <i>Journal of Hepatology</i> , 2020 , 72, 250-261	13.4	263
55	Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020 , 52, 421-429	2.8	2
54	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021 , 73 Suppl 1, 158-191	11.2	63
53	Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Primary Care Diabetes</i> , 2021 , 15, 52-58	2.4	10
52	Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. <i>Hepatology Communications</i> , 2021 , 5, 133-143	6	9
51	Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 223-238	24.2	228
50	Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. <i>Scientific Reports</i> , 2021 , 11, 2557	4.9	9
49	Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 45-55	5.3	6
48	Changes in patient background and prognosis after hepatectomy for hepatocellular carcinoma by hepatitis virus infection status: New trends in Japan. <i>Annals of Gastroenterological Surgery</i> , 2021 , 5, 553-566	4.3	0
47	Metformin attenuates synergic effect of diabetes mellitus and Helicobacter pylori infection on gastric cancer cells proliferation by suppressing PTEN expression. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 4534-4542	5.6	3
46	Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. <i>Gut and Liver</i> , 2021 , 15, 827-840	4.8	4
45	Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021 , 14, 1563-1574	3.4	2
44	Additional Inhibition of Wnt/ β Catenin Signaling by Metformin in DAA Treatments as a Novel Therapeutic Strategy for HCV-Infected Patients. <i>Cells</i> , 2021 , 10,	7.9	0
43	Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
42	The Prevention and Control of Cancer by Metformin in Patients with Type 2 Diabetes: A Systematic Mapping Review.		
41	Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 613-623	5.3	2

40	Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2021 , 44, 1937-1944	2.7	1
39	Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 46, 101781	2.4	1
38	The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature. <i>Biomolecules</i> , 2021 , 11,	5.9	5
37	High HbA1c is a risk factor for complications after hepatectomy and influences for hepatocellular carcinoma without HBV and HCV infection. <i>Hepatobiliary Surgery and Nutrition</i> , 2021 , 10, 454-463	2.1	1
36	Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus. <i>Biomolecules</i> , 2021 , 11,	5.9	2
35	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021 , 4, e352	2.2	
34	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. <i>Diabetes and Metabolism</i> , 2021 , 47, 101272	5.4	5
33	Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy. <i>Annals of Translational Medicine</i> , 2019 , 7, 739	3.2	2
32	Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. <i>PLoS ONE</i> , 2020 , 15, e0244293	3.7	0
31	Hepatocellular Carcinoma in 2021: An Exhaustive Update. <i>Cureus</i> , 2021 , 13, e19274	1.2	5
30	Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. <i>Hepatology Communications</i> , 2021 ,	6	0
29	Metabolic Syndrome and Liver Cancer. 2021 , 1-19		0
28	Gene expression profile analysis reveals the effect of metformin treatment on HepG2 cells. <i>Biocell</i> , 2022 , 46, 961-967	1.9	
27	Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis. <i>Journal of Clinical and Translational Hepatology</i> , 2022 , 000, 000-000	5.2	
26	S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. <i>Zeitschrift Fur Gastroenterologie</i> , 2022 , 60, e56-e130	1.6	0
25	Chemopreventive Effects of Concomitant or Individual Use of Statins, Aspirin, Metformin, and Angiotensin Drugs: A Study Using Claims Data of 23 Million Individuals.. <i>Cancers</i> , 2022 , 14,	6.6	0
24	Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease.. <i>Frontiers in Medicine</i> , 2022 , 9, 839456	4.9	1
23	Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2

22	Diabetes Medications and Risk of Hepatocellular Carcinoma.. <i>Hepatology</i> , 2022 ,	11.2	3
21	Aspirin Use and the Risk of Hepatocellular Carcinoma: A Meta-analysis.. <i>Journal of Clinical Gastroenterology</i> , 2022 ,	3	0
20	II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiolog� y diagn�stico. <i>Revista De Gastroenterolog� De M�xico</i> , 2022 ,	0.7	
19	The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis.. <i>Revista De Gastroenterolog� De M�xico (English Edition)</i> , 2022 ,	0.2	
18	Presentation_1.pdf. 2020 ,		
17	Identification of critical genes and pathways associated with hepatocellular carcinoma and type 2 diabetes mellitus using integrated bioinformatics analysis. <i>Informatics in Medicine Unlocked</i> , 2022 , 30, 100956	5.3	0
16	Metformin decreases Cyp26a1 to prevent hepatocarcinogenesis through down- regulating CD8+ T cells.		0
15	Clinical features and outcomes of NAFLD-related hepatocellular carcinoma. <i>Lancet Oncology, The</i> , 2022 , 23, e243	21.7	0
14	Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. 2022 , 12,		0
13	Metabolic Syndrome and Liver Cancer. 2022 , 87-104		0
12	Chemoprevention of Hepatocellular Carcinoma with Statins, Aspirin and Metformin: Systematic Review and Meta-Analysis of Matched Studies.		0
11	Holistic Management of Hepatocellular Carcinoma: The Hepatologist's Comprehensive Playbook.		0
10	Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study. 13,		0
9	Lifestyle and Genetic Modifiers of Liver Disease Progression. 2022 , 29-41		0
8	The Risk of Multiple Myeloma Is Reduced in Metformin Initiators: A Retrospective Cohort Study in Taiwanese Patients with Type 2 Diabetes Mellitus. 2022 , 14, 5637		0
7	Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis.		0
6	Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. 2022 ,		0
5	Metformin use and Occurrence of Hepatocellular Carcinoma in Patients with Type II Diabetes Mellitus: A Systematic Review. 2023 , 0		0

- 4 Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. 1
- 3 Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study. 0
- 2 Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome. **2022**, 21, 194-203 0
- 1 S3-Leitlinie Diagnostik und Therapie biliärer Karzinome [Langversion. **2023**, 61, e92-e156 0